Chinese drug regulators approved Haisco Pharmaceutical Group's (SHE:002653) HSK51155 tablets, according to a Wednesday filing with the Shenzhen bourse.
The pain reliever, a non-opioid analgesic, is seen to reduce adverse reactions and addiction risks, the company said in its filing.